These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 26645975)

  • 1. Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras.
    Li P; Wong YN; Armstrong K; Haas N; Subedi P; Davis-Cerone M; Doshi JA
    Cancer Med; 2016 Feb; 5(2):169-81. PubMed ID: 26645975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of targeted therapy on overall survival in advanced renal cancer: a study of the national surveillance epidemiology and end results registry database.
    Vaishampayan U; Vankayala H; Vigneau FD; Quarshie W; Dickow B; Chalasani S; Schwartz K
    Clin Genitourin Cancer; 2014 Apr; 12(2):124-9. PubMed ID: 24225251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry analysis of 28,252 patients.
    Shek D; Tomlinson B; Brown M; Brunson A; Pan CX; Lara PN
    Clin Genitourin Cancer; 2012 Jun; 10(2):93-8. PubMed ID: 22382008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Survival Associated With Use of Targeted vs Nontargeted Therapy in Medicare Patients With Metastatic Renal Cell Carcinoma.
    Li P; Jahnke J; Pettit AR; Wong YN; Doshi JA
    JAMA Netw Open; 2019 Jun; 2(6):e195806. PubMed ID: 31199450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era.
    Pal SK; Nelson RA; Vogelzang N
    PLoS One; 2013; 8(5):e63341. PubMed ID: 23658823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER-Medicare Database Analysis.
    Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Perez JR; Agarwal N; Vogelzang NJ
    Clin Genitourin Cancer; 2017 Aug; 15(4):e573-e582. PubMed ID: 28139444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Racial disparities in survival among patients with advanced renal cell carcinoma in the targeted therapy era.
    Rose TL; Deal AM; Krishnan B; Nielsen ME; Smith AB; Kim WY; Milowsky MI
    Cancer; 2016 Oct; 122(19):2988-95. PubMed ID: 27341404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival trends among patients with advanced renal cell carcinoma in the United States.
    Shah BK; Ghimire KB
    Urol Int; 2015; 94(2):133-6. PubMed ID: 25138899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing improvements in metastatic renal cell carcinoma systemic treatments from the pre-cytokine to the immune checkpoint inhibitor eras: a retrospective analysis of real-world data.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Jpn J Clin Oncol; 2021 Apr; 51(5):793-801. PubMed ID: 33324983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in the overall survival of patients with metastatic renal cell carcinoma in the era of immune-checkpoint inhibitors.
    Adhikari A; Sapkota S; Gogia S; Kc O
    Cancer Epidemiol; 2024 Oct; 92():102639. PubMed ID: 39146874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival trends among patients with metastatic melanoma in the pretargeted and the post-targeted era: a US population-based study.
    Uprety D; Bista A; Chennamadhavuni A; Niroula A; Jafri SIM; Smith A; Arjyal L
    Melanoma Res; 2018 Feb; 28(1):56-60. PubMed ID: 29023264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era.
    Conti SL; Thomas IC; Hagedorn JC; Chung BI; Chertow GM; Wagner TH; Brooks JD; Srinivas S; Leppert JT
    Int J Cancer; 2014 May; 134(9):2245-52. PubMed ID: 24135850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors.
    Santoni M; Conti A; Partelli S; Porta C; Sternberg CN; Procopio G; Bracarda S; Basso U; De Giorgi U; Derosa L; Rizzo M; Ortega C; Massari F; Iacovelli R; Milella M; Di Lorenzo G; Buti S; Cerbone L; Burattini L; Montironi R; Santini D; Falconi M; Cascinu S
    Ann Surg Oncol; 2015; 22(6):2094-100. PubMed ID: 25472645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A gap in disease-specific survival between younger and older adults with de novo metastatic renal cell carcinoma: results of a SEER database analysis.
    Nelson RA; Vogelzang N; Pal SK
    Clin Genitourin Cancer; 2013 Sep; 11(3):303-10. PubMed ID: 23647940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in Metastatic Kidney Cancer Survival From the Cytokine to the Targeted Therapy Era.
    Macleod LC; Tykodi SS; Holt SK; Wright JL; Lin DW; Tretiakova MS; True LD; Gore JL
    Urology; 2015 Aug; 86(2):262-8. PubMed ID: 26199164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapies in children with renal cell carcinoma (RCC): An International Society of Pediatric Oncology-Renal Tumor Study Group (SIOP-RTSG)-related retrospective descriptive study.
    Sprokkerieft J; van der Beek JN; Spreafico F; Selle B; Thebaud E; Chowdhury T; Brok J; Ottóffy G; Sun X; Ramírez Villar GL; Sagoyan G; Segers H; Doganis D; Serra A; Lemelle L; Graf N; Verschuur AC; Tytgat GAM; van den Heuvel-Eibrink MM
    Cancer Med; 2024 Jan; 13(1):e6782. PubMed ID: 39102694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of survival rates in patients with metastatic renal cell carcinoma according to treatment era including cytokine and targeted therapy.
    Takagi T; Kondo T; Kennoki T; Iizuka J; Kobayashi H; Hashimoto Y; Tanabe K
    Jpn J Clin Oncol; 2013 Apr; 43(4):439-43. PubMed ID: 23303839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
    Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
    J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era.
    Abern MR; Scosyrev E; Tsivian M; Messing EM; Polascik TJ; Dudek AZ
    Anticancer Res; 2014 May; 34(5):2405-11. PubMed ID: 24778051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective study of pediatric and adolescent renal cell carcinoma: A report from the Children's Oncology Group AREN0321 study.
    Geller JI; Cost NG; Chi YY; Tornwall B; Cajaiba M; Perlman EJ; Kim Y; Mullen EA; Glick RD; Khanna G; Daw NC; Ehrlich P; Fernandez CV; Dome JS;
    Cancer; 2020 Dec; 126(23):5156-5164. PubMed ID: 32926409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.